Hyper-DREAM, a Multimodal Digital Transformation Hypertension Management Platform Integrating Large Language Model and Digital Phenotyping: Multicenter Development and Initial Validation Study.

Abstract

Within the mHealth framework, systematic research that collects and analyzes patient data to establish comprehensive digital health archives for hypertensive patients, and leverages large language models (LLMs) to assist clinicians in health management and Blood Pressure (BP) control remains limited. In this study, our aims to describe the design, development and usability evaluation process of a management platform (Hyper-DREAM) for hypertension. Our multidisciplinary team employed an iterative design approach over the course of a year to develop the Hyper-DREAM platform. This platform's primary functionalities encompass multimodal data collection (personal hypertensive digital phenotype archive), multimodal interventions (BP measurement, medication assistance, behavior modification, and hypertension education) and multimodal interactions (clinician-patient engagement and BP Coach component). In August 2024, the mHealth App Usability Questionnaire (MAUQ) was conducted involving 51 hypertensive patients recruited from three distinct centers. In parallel, six clinicians engaged in management activities and contributed feedback via the Doctor's Software Satisfaction Questionnaire (DSSQ). Concurrently, a real-world comparative experiment was conducted to evaluate the usability of the BP Coach, ChatGPT-4o Mini, ChatGPT-4o and clinicians. The comparative experiment demonstrated that the BP Coach achieved significantly higher scores in utility (mean scores 4.05, SD 0.87) and completeness (mean scores 4.12, SD 0.78) when compared to ChatGPT-4o Mini, ChatGPT-4o, and clinicians. In terms of clarity, the BP Coach was slightly lower than clinicians (mean scores 4.03, SD 0.88). In addition, the BP Coach exhibited lower performance in conciseness (mean scores 3.00, SD 0.96). Clinicians reported a marked improvement in work efficiency (2.67 vs. 4.17, P < .001) and experienced faster and more effective patient interactions (3.0 vs. 4.17, P = .004). Furthermore, the Hyper-DREAM platform significantly decreased work intensity (2.5 vs. 3.5, P = .01) and minimized disruptions to daily routines (2.33 vs. 3.55, P = .004). The Hyper-DREAM platform demonstrated significantly greater overall satisfaction compared to the WeChat-based standard management (3.33 vs. 4.17, P = .01). Additionally, clinicians exhibited a markedly higher willingness to integrate the Hyper-DREAM platform into clinical practice (2.67 vs. 4.17, P < .001). Furthermore, patient management time decreased from 11.5 min (SD 1.87) with Wechat-based standard management to 7.5 min (SD 1.84, P = .01) with Hyper-DREAM. Hypertensive patients reported high satisfaction with the Hyper-DREAM platform, including ease of use (mean scores 1.60, SD 0.69), system information arrangement (mean scores 1.69, SD 0.71), and usefulness (mean scores 1.57, SD 0.58). In conclusion, our study presents Hyper-DREAM, a novel artificial intelligence-driven platform for hypertension management, designed to alleviate clinician workload and exhibiting significant promise for clinical application. The Hyper-DREAM platform is distinguished by its user-friendliness, high satisfaction rates, utility, and effective organization of information. Furthermore, the BP Coach component underscores the potential of LLMs in advancing mHealth approaches to hypertension management.